<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825836</url>
  </required_header>
  <id_info>
    <org_study_id>MS200662_0001</org_study_id>
    <secondary_id>2016-000286-23</secondary_id>
    <nct_id>NCT02825836</nct_id>
  </id_info>
  <brief_title>Phase I/II, First in Human, Dose Escalation Trial of TL 895 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Small Lymphocytic Lymphoma</brief_title>
  <official_title>Phase I/II, First in Human, Dose Escalation Trial of TL 895 in Subjects With Relapsed/Refractory B-Cell Malignancies and Expansion in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Small Lymphocytic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Telios Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Telios Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine the safety and tolerability of TL-895.&#xD;
      There are 2 parts of this study. Part 1 tested increasing doses of TL-895 to identify the&#xD;
      recommended safe dose for participants with relapsed/refractory (R/R) B cell malignancies who&#xD;
      failed at least 1 but no more than 3 prior therapies. Part 1 of this study is no longer&#xD;
      enrolling participants.&#xD;
&#xD;
      Part 2 of this study will test different doses of TL-895 in participants with R/R CLL or SLL&#xD;
      who have failed at least 1 prior therapy. Part 2 of this study is randomized (like the flip&#xD;
      of a coin) to receive a specific treatment dose. If someone participates in Part 2, the dose&#xD;
      they receive will be either 100mg twice a day or 150mg twice a day. Every participant in this&#xD;
      study will receive TL-895.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2016</start_date>
  <completion_date type="Anticipated">February 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 (Dose Escalation): DLTs (Dose Limiting Toxicities) during Cycle 1</measure>
    <time_frame>Baseline up to the end of cycle 1 (28 days)</time_frame>
    <description>DLT is defined as any of the adverse event (AEs) of a certain grade or above, related to drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 (Dose Expansion): Overall Response Rate (ORR)</measure>
    <time_frame>Baseline up to end of study (2 years after last patient enrolled)</time_frame>
    <description>The proportion of subjects achieving CR, CRi, nodular partial response (nPR), partial response (PR), or PR with lymphocytosis (PR-L) at any time while on the study based on iwCLL response criteria (2), as assessed by investigators</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 (Dose Escalation): Best Overall Response (BOR)/Progression Free Survival (PFS)</measure>
    <time_frame>Baseline up to 6 months on treatment</time_frame>
    <description>Defined by the length of time during the treatment of the disease, that a participant lives with the disease but it does not get worse based on investigator assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 (Dose Expansion): Overall CR/CRi rate</measure>
    <time_frame>Baseline up to end of study (2 years after last patient enrolled)</time_frame>
    <description>The proportion of subjects achieving CR/CRi based on iwCLL response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Duration of Clinical Response (DOR)</measure>
    <time_frame>Baseline up to end of study (2 years after last patient enrolled)</time_frame>
    <description>Time from initial response to disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to end of study (2 years after last patient enrolled)</time_frame>
    <description>Incidence, nature, severity of treatment-emergent adverse events (TEAEs), and deaths, including cause of death, from screening up to the end of study visit of participants with CLL/SLL who have failed at least 1 line of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Assessment of Safety and Tolerability via Clinical Measurements</measure>
    <time_frame>Baseline up to end of study (2 years after last patient enrolled)</time_frame>
    <description>Assessments including but not limited to clinical laboratory measurements, ECGs, vital signs, and ECOG performance</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Relapsed/Refractory B Cell Malignancies</condition>
  <condition>Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>TL-895 80/160 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received TL-895 80 mg powder in capsule (PiC) orally once daily (OD) for 3 days followed by TL-895 160 mg OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TL-895 300 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received TL-895 300 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TL-895 600 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received TL-895 600 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TL-895 300 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received TL-895 300 mg PiC orally twice daily (BID) in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TL-895 900 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received TL-895 900 mg PiC orally QD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TL-895 100 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received TL-895 100 mg BID orally BID with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TL-895 150 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received TL-895 150 mg BID orally BID with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TL-895</intervention_name>
    <description>All participants will receive TL-895 at the dose assigned at enrollment until disease progression, withdrawal of consent, or discontinuation from the study.</description>
    <arm_group_label>TL-895 100 mg BID</arm_group_label>
    <arm_group_label>TL-895 150 mg BID</arm_group_label>
    <arm_group_label>TL-895 300 mg BID</arm_group_label>
    <arm_group_label>TL-895 300 mg QD</arm_group_label>
    <arm_group_label>TL-895 600 mg QD</arm_group_label>
    <arm_group_label>TL-895 80/160 mg QD</arm_group_label>
    <arm_group_label>TL-895 900 mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Relapsed/refractory CLL or relapsed/refractory SLL&#xD;
&#xD;
          -  ECOG performance status of ≤ 2&#xD;
&#xD;
          -  Adequate hematologic, hepatic, and renal functions&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Prior treatment with any BTK or PI3K inhibitors&#xD;
&#xD;
          -  History of major organ transplant&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John Mei</last_name>
    <email>jmei@teliospharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikki Stuart</last_name>
    <email>nzona@teliospharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem - Borgyógyászati Klinika</name>
      <address>
        <city>Debrecen</city>
        <zip>4002</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eger Markhot Ferenc Kórház</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi - Istituto di Ematologia e Oncologia Medica</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Examen sp. z o. o.</name>
      <address>
        <city>Skorzewo</city>
        <state>Poznań</state>
        <zip>60-185</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pratia MCM Krakow</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli Oddzial Hematologiczny</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki</name>
      <address>
        <city>Opole</city>
        <zip>46-020</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Przychodnie Medyczne</name>
      <address>
        <city>Toruń</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Regional Clinical Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit Enterprise Regional Center of Oncology</name>
      <address>
        <city>Kharkiv</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital #4</name>
      <address>
        <city>Kyiv</city>
        <zip>03110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mykolaiv Regional Clinical Hospital</name>
      <address>
        <city>Mykolaiv</city>
        <zip>54058</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barts Hospital - Cancer Centre</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals - NIHR/Wellcome Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital - Dept of Haematology</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <reference>
    <citation>Eugenio Gaudio, Chiara Tarantelli, Emanuele Zucca, Davide Rossi, Anastasios Stathis, Francesco Bertoni. The two novel BTK-inhibitors M2951 and M7583 show in vivo anti-tumor activity in pre-clinical models of B cell lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4182. doi:10.1158/1538-7445.AM2017-4182</citation>
  </reference>
  <reference>
    <citation>Samantha M. Goodstal, Jianguo Ma, Jing Lin, Timothy Crandall, Lindsey Crowley, Andrew Bender, Riham Iadevaia and Anderson Clark. M7583 Is a Highly Selective and Potent Second Generation BTK Inhibitor for Treatment of B-Cell Malignancies. Blood 2017 130:3845.</citation>
  </reference>
  <reference>
    <citation>Wojciech Jurczak, Simon Rule, William Townsend, David Tucker, Martin Dyroff, Barbara Sarholz, Jürgen Scheele, John G. Gribben and Pier Luigi Zinzani. First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes. Blood 2017 130:2778.</citation>
  </reference>
  <reference>
    <citation>Simon Rule, David Tucker, Anup Kalapur, Barbara Sarholz, Jürgen Scheele, Pier Luigi Zinzani. Phase I/II, first in human trial of the Bruton's tyrosine kinase inhibitor (BTKi) M7583 in patients with B cell malignancies. J Clin Oncol 35, 2017 (suppl; abstr e14101).</citation>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 1, 2016</study_first_submitted>
  <study_first_submitted_qc>July 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TL-895</keyword>
  <keyword>Tyrosine Kinase Inhibitor</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Open</keyword>
  <keyword>Phase I</keyword>
  <keyword>Phase II</keyword>
  <keyword>CLL</keyword>
  <keyword>SLL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

